Biologic therapies target aberrant pathways in diseases including diabetes, cancer and autoimmune disorders. Despite recent scientific advances, patient access to these agents can be limited. Biosimilars are designed to be highly similar to the originator biologic, targeting the same biological pathways, with comparable efficacy and safety. Biosimilars have the advantage of lower treatment costs, offering the potential for increased clinical use and patient access. Several biosimilars are approved for clinical use in the USA and Europe; however, there is a lack of awareness about biosimilars among healthcare providers and patients. This overview of the scientific basis of biosimilars and current indications aim to enhance discussions with patients and increase understanding of the role of biosimilars in individual treatment plans.
Talking to patients about biosimilars / Y.Y. Janjigian, M. Bissig, G. Curigliano, J. Coppola, M. Latymer. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 14:23(2018 Oct), pp. 2403-2414.
|Titolo:||Talking to patients about biosimilars|
|Parole Chiave:||biosimilar; healthcare provider; patient access; patient communication; regulatory pathway; totality of evidence; Animals; Biosimilar Pharmaceuticals; Europe; Health Personnel; Humans; Neoplasms; Treatment Outcome; United States; Oncology; Cancer Research|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||ott-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.2217/fon-2018-0044|
|Appare nelle tipologie:||01 - Articolo su periodico|